CIK 0001746473 · Non-accelerated filer<br>Smaller reporting company
PLIANT THERAPEUTICS, INC.
Sign in to watch- Ticker
- PLRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474272481
- Phone
- 650-481-6770
- Business address
- 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 90 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +74,250 | 74,250 | ||
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −124,000 | 0 | ||
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +124,000 | 124,000 | ||
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −76,200 | 0 | ||
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +76,200 | 76,200 | ||
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −110,500 | 0 | ||
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +110,500 | 110,500 | ||
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −113,300 | 0 | ||
| 2026-04-17 | Cummings Keith Lamont Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +113,300 | 113,300 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Returned to the company · Stock Option (Right to Buy) | −146,841 | 0 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Grant or award · Stock Option (Right to Buy) | +146,841 | 146,841 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Returned to the company · Stock Option (Right to Buy) | −327,262 | 0 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Grant or award · Stock Option (Right to Buy) | +327,262 | 327,262 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Returned to the company · Stock Option (Right to Buy) | −250,000 | 0 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Returned to the company · Stock Option (Right to Buy) | −440,000 | 0 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Grant or award · Stock Option (Right to Buy) | +440,000 | 440,000 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Returned to the company · Stock Option (Right to Buy) | −206,300 | 0 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Grant or award · Stock Option (Right to Buy) | +206,300 | 206,300 | ||
| 2026-04-17 | Coulie Bernard President and CEO | Returned to the company · Stock Option (Right to Buy) | −256,300 | 0 |
Page 2 of 8 · 160 trades